$136.63
-1.84-1.33%
In chiusura: -
$136.75
0.120.09%
After hour: Oct 10, 5:46 PM EDT
Comments
Loading...
Stime degli utili, EPS e fatturato
Neurocrine Biosciences segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Data degli utili
ott 28
Stima EPS
$1.890
Stima dei ricavi trimestrali
$745.61M
Ricavi annuali
(a partire da giu 30)
(a partire da giu 30)
$2.51B
Analizza lo storico degli utili di Neurocrine Biosciences utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
NBIX | Neurocrine Biosciences | $1.81 | $1.89 | — | — | $622.10M | $745.61M | — | — | 10/28/2025 | |
NBIX | Neurocrine Biosciences | $1.63 | $1.27 | $1.65 | 29.92% | $590.20M | $651.25M | $687.50M | 5.57% | 07/30/2025 | |
NBIX | Neurocrine Biosciences | $1.20 | $1.09 | $0.70 | -35.78% | $515.30M | $560.97M | $572.60M | 2.07% | 05/05/2025 | |
NBIX | Neurocrine Biosciences | $1.54 | $1.71 | $1.69 | -1.17% | $515.20M | $628.96M | $627.70M | -0.20% | 02/06/2025 | |
NBIX | Neurocrine Biosciences | $1.54 | $1.51 | $1.81 | 19.87% | $498.80M | $600.63M | $622.10M | 3.57% | 10/30/2024 | |
NBIX | Neurocrine Biosciences | $1.25 | $1.03 | $1.63 | 58.25% | $452.70M | $547.07M | $590.20M | 7.88% | 08/01/2024 | |
NBIX | Neurocrine Biosciences | -$0.51 | $1.01 | $1.20 | 18.81% | $420.40M | $511.97M | $515.30M | 0.65% | 05/01/2024 | |
NBIX | Neurocrine Biosciences | $1.24 | $1.15 | $1.54 | 33.91% | $412.00M | $518.13M | $515.20M | -0.57% | 02/07/2024 | |
NBIX | Neurocrine Biosciences | $1.08 | $0.98 | $1.54 | 57.14% | $387.90M | $469.92M | $498.80M | 6.15% | 10/31/2023 | |
NBIX | Neurocrine Biosciences | $0.84 | $0.77 | $1.25 | 62.34% | $378.20M | $448.89M | $452.70M | 0.85% | 08/01/2023 | |
NBIX | Neurocrine Biosciences | $0.30 | $0.13 | -$0.51 | -492.31% | $310.60M | $409.35M | $420.40M | 2.70% | 05/03/2023 | |
NBIX | Neurocrine Biosciences | $0.04 | $1.14 | $1.24 | 8.77% | $312.00M | $409.09M | $412.00M | 0.71% | 02/06/2023 | |
NBIX | Neurocrine Biosciences | $0.64 | $0.80 | $1.08 | 35.00% | $296.00M | $376.50M | $387.90M | 3.03% | 11/01/2022 | |
NBIX | Neurocrine Biosciences | $0.63 | $0.59 | $0.84 | 42.37% | $288.90M | $341.31M | $378.20M | 10.81% | 08/04/2022 | |
NBIX | Neurocrine Biosciences | $0.49 | $0.34 | $0.30 | -11.76% | $236.60M | $303.40M | $310.60M | 2.37% | 05/04/2022 | |
NBIX | Neurocrine Biosciences | $0.91 | $0.52 | $0.04 | -92.31% | $247.90M | $316.79M | $312.00M | -1.51% | 02/11/2022 | |
NBIX | Neurocrine Biosciences | $0.97 | $0.60 | $0.64 | 6.67% | $258.50M | $297.65M | $296.00M | -0.55% | 11/01/2021 | |
NBIX | Neurocrine Biosciences | $1.42 | $0.49 | $0.63 | 28.57% | $302.40M | $274.38M | $288.90M | 5.29% | 08/03/2021 | |
NBIX | Neurocrine Biosciences | $0.82 | $0.51 | $0.49 | -3.92% | $237.10M | $250.63M | $236.60M | -5.60% | 05/05/2021 | |
NBIX | Neurocrine Biosciences | $1.05 | $0.54 | $0.91 | 68.52% | $244.10M | $262.40M | $247.90M | -5.53% | 02/04/2021 | |
NBIX | Neurocrine Biosciences | $0.90 | $0.22 | $0.97 | 340.91% | $222.09M | $283.04M | $258.50M | -8.67% | 11/09/2020 |
Neurocrine Biosciences (NBIX) Guadagno per azione
Importo a sorpresa sugli utili trimestrali
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-07-30 | $1.65 | $1.27 | 29.9 % |
| Q1 | 2025-05-05 | $0.70 | $1.09 | -35.8 % |
| Q4 | 2025-02-06 | $1.69 | $1.71 | -1.17 % |
| Q3 | 2024-10-30 | $1.81 | $1.51 | 19.9 % |
Neurocrine Biosciences (NBIX) Entrate
Importo sorpresa sulle entrate trimestrali
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | 2025-07-30 | $687.50M | $651.25M | 5.57 % |
| Q1 | 2025-05-05 | $572.60M | $560.97M | 2.07 % |
| Q4 | 2025-02-06 | $627.70M | $628.96M | -0.20 % |
| Q3 | 2024-10-30 | $622.10M | $600.63M | 3.57 % |
FAQ
Quando Neurocrine Biosciences (NASDAQ:NBIX) riporterà gli utili?
Si prevede che Neurocrine Biosciences (NBIX) fornisca risultati il ottobre 28, 2025. Gli ultimi risultati sono stati pubblicati il luglio 30, 2025 per il Q2.
Quali sono stati gli ultimi utili per azione (EPS) di Neurocrine Biosciences (NASDAQ:NBIX)?
L'EPS effettivo era $1.65, che superato la stima di $1.27.
Quali sono state le entrate di Neurocrine Biosciences (NASDAQ:NBIX)?
Le entrate effettive sono state $687.5M, che superato la stima di $651.2M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.